A co-creation organization will be established with at least three parties to succeed Kyorin Pharmaceutical’s generic drug business. Daito Pharmaceutical Co.,Ltd. will hold 49.1%, Meiji Seika Pharma 36.0%, and DBJ 14.9%. The co-creation organization is scheduled to be established in December 2026; as a prior transaction, an absorption-type company split is scheduled for March 31, 2027, and the share transfer is scheduled for April 1, 2027. The target business excludes the AG business.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4577","jir_company_name":"Daito Pharmaceutical Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4577-20260930-01.pdf","jir_short_summary":"A co-creation organization will be established with at least three parties to succeed Kyorin Pharmaceutical's generic drug business. Daito Pharmaceutical Co.,Ltd. will hold 49.1%, Meiji Seika Pharma 36.0%, and DBJ 14.9%. The co-creation organization is scheduled to be established in December 2026; as a prior transaction, an absorption-type company split is scheduled for March 31, 2027, and the share transfer is scheduled for April 1, 2027. The target business excludes the AG business.","jir_summary":"### Overview\nDaito Pharmaceutical Co.,Ltd., Meiji Seika Pharma Co.,Ltd., and Development Bank of Japan Inc. will establish a jointly funded company, \"Pharmaceutical Co-creation Organization Co., Ltd.\", to succeed Kyorin Pharmaceutical Co.,Ltd.'s generic drug business. The co-creation organization aims to achieve high quality and stable supply through integrated operations of manufacturing, quality assurance, and supply chain. Through the share transfer, the co-creation organization is scheduled to acquire the shares of the company subject to this transaction, and as a prior transaction an absorption-type company split will be implemented to transfer the target business (excluding the AG business).\n\n### Schedule and Impact\nThe signing of this agreement is scheduled for 2026-09-30, the co-creation organization's establishment is scheduled for December 2026, the effective date of the prior transaction is scheduled for 2027-03-31, and the execution date of succession is scheduled for 2027-04-01. DBJ has decided to invest through a Supply Chain Resilience Fund and has indicated that this will contribute to strengthening the competitiveness of the regional pharmaceutical industry. While the business succession is expected to lead to medium- to long-term improvements in performance and organizational strength, the direct impact on consolidated results for the current fiscal period is considered minimal.","jir_financial_highlights":"Investment Ratios: Daito Pharmaceutical Co.,Ltd. 49.1%, Meiji Seika Pharma 36.0%, DBJ 14.9% (New establishment plan)\nCo-creation Organization Establishment Period: December 2026 (scheduled) (Scheduled)\nEffective Date of This Prior Transaction: 2027-03-31 (scheduled) (Scheduled)\nExecution Date of Succession (Execution Date of This Share Transfer): 2027-04-01 (scheduled) (Scheduled)","jir_category":"","jir_hashtags":"#DaitoPharmaceutical_IR, #M&A_Alliance","jir_key_figures":"Investment Ratios: Daito Pharmaceutical Co.,Ltd. 49.1%, Meiji Seika Pharma 36.0%, DBJ 14.9%\nCo-creation Organization Establishment Date: December 2026 (scheduled)\nEffective Date of This Prior Transaction: 2027-03-31 (scheduled)","jir_meta_title":"Daito Pharmaceutical Co.,Ltd. to Establish Joint Investment Vehicle to Succeed Kyorin Pharmaceutical's Generic Drug Business\uff5cDecember 2026","jir_meta_description":"Daito Pharmaceutical Co.,Ltd., Meiji Seika Pharma, and DBJ will establish a jointly funded pharmaceutical co-creation organization to succeed Kyorin Pharmaceutical's generic drug business. The prior transaction is scheduled for March 2027 and the share transfer for April 2027. Details of the capital partnership aimed at strengthening regional supply chain resilience.","jir_og_title":"Daito Pharmaceutical Co.,Ltd. to Establish Joint Investment Organization to Succeed Kyorin Pharmaceutical's Generic Drug Business","jir_og_description":"Daito Pharmaceutical Co.,Ltd., Meiji Seika Pharma, and DBJ will jointly establish a pharmaceutical co-creation organization to succeed Kyorin Pharmaceutical's generic drug business. Overview of the schedule and impact on the regional economy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56861,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-125031","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n